We also demonstrated that Inhibitor-4 arrests the cell cycle in breast cancer cells without affecting normal cells (Figure 4 and Figure S4), which demonstrates an improvement over BCl-121, a previously-developed SMYD3 inhibitor. Here, SMYD3 is linked to breast carcinoma.